The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
Aeglea | Common | 00773J103 | 1,849 | 240,500 | SH | DFND | 240,500 | 0 | 0 | ||
Chiasma | Common | 16706W102 | 1,827 | 370,671 | SH | DFND | 370,671 | 0 | 0 | ||
Crispr | NAMEN AKT | H17182108 | 25,745 | 628,398 | SH | DFND | 628,398 | 0 | 0 | ||
Cymabay | Common | 23257D103 | 670 | 131,036 | SH | DFND | 131,036 | 0 | 0 | ||
Exicure | Common | 30205M101 | 15,750 | 6,250,000 | SH | DFND | 6,250,000 | 0 | 0 | ||
Ocugen | Common | 43358V109 | 20 | 7,111 | SH | DFND | 7,111 | 0 | 0 | ||
Obseva | Common | H5861P103 | 731 | 87,999 | SH | DFND | 87,999 | 0 | 0 | ||
Paratek | Common | 699374302 | 4,508 | 1,041,131 | SH | DFND | 1,041,131 | 0 | 0 | ||
Personalis | Common | 71535D106 | 79,941 | 5,449,294 | SH | DFND | 5,449,294 | 0 | 0 | ||
Proteon | Common | 74371L109 | 525 | 2,017,872 | SH | DFND | 2,017,872 | 0 | 0 | ||
Sientra | Common | 82621J105 | 15,469 | 2,390,843 | SH | DFND | 2,390,843 | 0 | 0 | ||
Sierra Oncology | Common | 82640U107 | 83 | 216,667 | SH | DFND | 216,667 | 0 | 0 | ||
Soleno | Common | 834203200 | 6,911 | 4,669,272 | SH | DFND | 4,669,272 | 0 | 0 | ||
Verona | SPONDS ADR | 925050106 | 4,122 | 901,943 | SH | DFND | 901,943 | 0 | 0 |